tbuckley/cabot-search huggingface dataset:
EXTH-82. HIGH NOTCH1 EXPRESSION AND WILD-TYPE P53 DEFINE SYNERGISTIC ACTIVITY BY GAMMA SECRETASE INHIBITORS AND DOXORUBICIN IN GLIOBLASTOMAS
Authors: Chen Zhang, Emmanuel Martinez-Ledesma, Jie Ding, Feng Gao, Shaofang Wu, W K Alfred Yung, Dimpy Koul
Journal: Neuro-Oncology (2017)

Glioblastoma (GBM) remains one of the most lethal and difficult-to-treat cancers. The poor prognosis of GBM patients is due in part to its resistance to available treatments, which calls for development of novel therapeutic agents/regimen. In this study, we tested a series of patient-derived primary glioma stem cells (GSCs) to 3 GSIs (RO4929097, BMS-708163, and LY3039478) by sphere formation assay. GSI sensitivity was defined by statistically significant inhibition of sphere forming ability. 46% of the GSC lines showed significant impairment by both GSIs (p<0.05), which were defined as the GSI-sensitive GSCs. To identify a predictive signature, we performed enrichment and correlation analyses using RNA sequencing, RPPA, and methylation data of the GSI-sensitive and resistant GSCs. Analysis of integrated data identified GSI-sensitive GSCs harbored significantly elevated NOTCH expression (high NOTCH1 expression and low NOTCH1 methylation). In addition, GSI-sensitive cells showed increased P53 activity (increased expression of P53 targets-P21, BAX and TIGAR), high wild-type P53 frequencies, and decreased PI3K/AKT activity (high PTEN expression and low p-AKT-Thr308 expression) (p<0.05). As GSIs alone showed only modest efficacy, we turned to identifying a combination strategy to strengthen GSI effect on cell growth. We showed that concomitant inhibition of NOTCH signaling with GSI together with doxorubicin (induces DNA damage and thus restores P53 activity) had a synergistic growth inhibitory effect in P53 wild-type GSI-sensitive cells, confirming doxorubicin enhanced GSI efficacy in a subset of GBMs. In summary, we elucidated the genetic characteristics (high NOTCH, wild-type p53, and low PI3K/AKT) of GSI-sensitive GSCs and developed a combination strategy based on the genetic markers. High NOTCH1 expression and wild-type P53 predicted the synergistic effect of GSI and doxorubicin, providing a potential new therapeutic regimen for a molecularly selected subset of GBM patients.
PUB074 Programmed Death Ligand 1 (PD-L1) Expression in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
Authors: M. D'Arcangelo, M. Puccetti, S. Bravaccini, A. D'Incecco, C. Ligorio, L. Terracciano, S. Damiani, S. Ravaioli, M.M. Tumedei, C. Bennati, G. Minuti, S. Vecchiarelli, L. Landi, M. Incarbone, M. Milesi, F. Cappuzzo
Journal: Journal of Thoracic Oncology (2017)
MA 03.03 Nedaplatin plus Docetaxel versus Cisplatin plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung
Authors: S. Lu, Z. Chen, C. Hu, R. Xin-Ling, Y. Chen, Y. Song, Z. Qiong, Y. Fan, W. Gang, M. Zhi-Yong, J. Fang, Y. Qi-Tao, Z. Liu
Journal: Journal of Thoracic Oncology (2017)
P1.14-017 Impact of Systematic EBUS-TBNA Mediastinal Staging on Radical Radiotherapy Planning in NSCLC
Authors: N. Hardcastle, A. Cole, G. Turgeon, R. Thomas, B. Gearey, L. Irving, B. Jennings, T. Kron, D. Ball, D. Steinfort, S. Siva
Journal: Journal of Thoracic Oncology (2017)
Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study
Authors: P. Pronzato, G. Mustacchi, F. Riccardi, A. Turletti, A. Michelotti, C. Natoli, L. Livi, L. Del Mastro, M. Donadio, O. Garrone, M. Giordano, M. De Laurentiis, P. Marchetti, F. Montemurro, E. Romagnoli, S. De Placido, L. Biganzoli, M. Cazzaniga
Journal: Annals of Oncology (2017)
MA 11.11 Italian Nivolumab Expanded Access Program in Non-Squamous NSCLC Patients: Results in Never Smokers and EGFR Positive Patients
Authors: M. Garassino, E. Cortesi, F. Grossi, R. Chiari, H. Soto Parra, S. Cascinu, F. Cognetti, D. Turci, L. Blasi, C. Bengala, E. Mini, E. Baldini, T. Gamucci, G. Ceresoli, P. Antonelli, E. Vasile, C. Pinto, D. Galetta, M. Macerelli, F. De Marinis
Journal: Journal of Thoracic Oncology (2017)
P3.16-049 Surgery with Continued TKI Therapy After Acquiring Resistance to EGFR or ALK TKI
Authors: S. Ohara, Y. Kobayashi, T. Fujino, Y. Sesumi, M. Nishino, M. Chiba, M. Shimoji, K. Tomizawa, T. Takemoto, T. Mitsudomi
Journal: Journal of Thoracic Oncology (2017)
ACTR-02. DCC-2618, A NOVEL pan-KIT AND PDGFRa KINASE SWITCH CONTROL INHIBITOR, SHOWS ENCOURAGING SIGNAL IN A PATIENT (PT) WITH GLIOBLASTOMA (GBM)
Authors: John de Groot, Suzanne George, Albiruni Razak, Michael Gordon, Filip Janku, Keith Ligon, Patrick Wen, Sharon Friedlander, Daniel Flynn, Michael Kaufman, Jama Pitman, Rodrigo Ruiz-Soto, Bryan Smith, Deborah Westwood, Oliver Rosen, David Reardon
Journal: Neuro-Oncology (2017)

Non-clinical data suggest that PDGFRa plays an important role in the development and progression of human gliomas. To date, few PDGFRa inhibitors with CNS activity have been available. DCC-2618 was designed to potently inhibit the broadest range of mutations (mut) in KIT & PDGFRa kinases that emerge during tumor progession or on treatment. In a dose-escalation study (NCT# 02571036) of oral DCC-2618 (QD or BID q28 days), pts with advanced malignancies with a molecular rationale for activity were eligible. MRI scans were performed initially every 2 cycles then every 3 cycles. We enrolled 4 GBM pts and 1 anaplastic astrocytoma (AA) pt with PDGFRa muts/ amplifications who had progressed after standard temozolomide chemoradiation (GBM) or temozolomide only (AA) and had received 0 to 5 salvage therapies. Three pts (2 GBM and 1 AA) had a triple amplification of PDGFRa, KIT and KDR (4q12 amplicon). Two GBM pts had activating PDGFRa mutations. Pts were treated at 20 mg (1 pt), 50 mg BID (2 pts) or 100 mg QD (2 pts). The per-protocol population (N=48) received doses up to 200 mg BID and DCC-2618 was well tolerated. One GBM pt with mut PDGFRa progressed after 6 weeks and one stopped treatment due to a tumor-related hemaorrhage on C1D12. Two of the three pts with triple amplifications progressed after 2 cycles while the third pt (GBM, 20 mg BID) achieved a PR per RANO after 9 cycles. This pt is currently in cycle 20 with a remarkable 94% tumor reduction. The durable partial response of >18 months in a GBM patient (94% tumor reduction) warrants further evaluation of DCC-2618 in gliomas. An expansion cohort for pts with KIT- and PDGFRa driven tumors was initiated to be able to better select the patient population with a likely benefit.
P2.14-014 Does Histological Subtype Affect Outcomes in Stereotactic Ablative Body Radiotherapy (SABR) for Lung Tumors?
Authors: B. Allos, S. Mascall, M. Vreugdenhil, S. Watkins, R. Stevenson, Q. Ghafoor
Journal: Journal of Thoracic Oncology (2017)
GENE-25. THE HDAC INHIBITOR AR42 ATTENUATES CROSSTALK BETWEEN TWO MUTUALLY-EXCLUSIVE GLIOMA STEM CELL SUBTYPES AND AUGMENTS IMMUNOTHERAPY WITH PD-1 CHECKPOINT BLOCKADE
Authors: Hai Yu, Marat Pavlyukov, Suojun Zhang, Soniya Bastola, Mutsuko Minata, Heba Allah Alsheikh, Kyung-Don Kang, Lyse Norian, N Kagaya, K Shinya, Ichiro Nakano
Journal: Neuro-Oncology (2017)

Accumulating evidence suggests that glioma stem-like cells (GSCs) play crucial roles in therapy resistance and recurrence of glioblastoma (GBM). Previously, we identified two mutually-exclusive GSC subtypes in GBM, termed mesenchymal (MES) and proneural (PN) GSCs, which co-exist in single tumors and contribute to distinct hierarchical cell populations. When compared, MES GSCs exhibited higher aggressiveness and radio-resistance than PN GSCs. In this study, we tested the hypothesis that PN and MES GSCs have inter-cellular crosstalk to promote GBM aggressiveness and heterogeneity. Co-culture of MES and PN GSC-containing cultures (glioma spheres) promoted both in vitro growth and in vivo tumorgenesity of PN glioma spheres. By a high throughput screening using the natural product libraries, we found several HDAC inhibitors selectively eliminate MES but not PN glioma spheres and block the intercellular signals from MES glioma spheres to promote aggressiveness of PN cells. To translate these pre-clinical data to the clinic, we focused on characterization of the newly developed pan-HDACi, AR42 in GSCs. AR42 treatment to the patient-derived MES glioma spheres attenuated their in vitro clonogenicity, in vivo tumor propagation and radio-resistance. Beyond direct tumor cell cytotoxicity, HDACi elevated the expression of adaptive immune checkpoint PD-L1 in a class I HDAC dependent way. Mechanistically, after HDAC inhibition, we observed an increase in binding of transcription factor STAT1 to PD-L1 promoter, which was attributed to increased histone acetylation. A combination of HDACi and anti-PD1 antibody improved the survival and reduced tumor burden in our syngeneic murine GBM models, with higher PD-L1 expression and cytotoxic T cell infiltration in mouse tumor tissue. Collectively, the results shed light on potential combinatorial therapeutic approaches, providing the rationale to combine AR42 with Nivolumab in the future clinical therapeutic development for GBM. The current status of the clinical development of AR42 for GBM will be discussed in detail.
Infections nosocomiales dans des hôpitaux universitaires de Lettonie, Lituanie et Suède : un protocole simple pour un contrôle de qualité
Authors: J Struwe, U Dumpis, J Gulbinovic, Å Lagergren, U Bergman
Journal: Eurosurveillance (2006)

La surveillance des infections nosocomiales est un parametre de bonnes pratiques cliniques souvent neglige dans les etablissements de soins, en raison de la charge de travail qu’elle implique en l’absence de systemes informatiques adequats. L’objectif de
Importante aumento de las infecciones por Salmonella en 2003 en los Países Bajos: ¿consecuencia de la ola de calor o del brote de gripe aviar?
Authors: W van Pelt, D. J Mevius, H G Stoelhorst, S Kovats, A. W van de Giessen, W J B Wannet, Y T H P Duynhoven
Journal: Eurosurveillance (2004)

En junio de 2003, el Centro nacional holandes de Salmonella dio a conocer un aumento significativo de la tasa de aislamiento de Salmonella Enteritidis, comparada con la de anos anteriores, en la mayoria de los laboratorios regionales de salud publica. A finales de 2003, este exceso era de 540 casos confirmados microbiologicamente para el conjunto de Holanda, lo que significaba 7.500 casos en exceso de gastroenteritis causada por S. Enteritidis en la poblacion general, o sea un aumento de 50% en relacion con anos precedentes. Estos resultados no pueden explicarse por el fuerte calor del verano de 2003. Argumentos cientificos solidos muestran que podria deberse a un aumento de la importacion de huevos contaminados por Salmonella, como consecuencia del brote de gripe aviaria concomitante.
Abstract 18664: Rate of Accuracy in a System of Cath Lab Activation - The RASCAL Study
Authors: Gustav Engvall, Mikolaj Skibniewski, Magnus Janzon, Ebo De Muinck, Joakim Alfredsson
Journal: Circulation (2013)

Primary PCI is the recommended treatment of choice for patients with STEMI. Treatment is based on ECG and symptoms alone why concern has been raised about overuse of invasive assessment. We designed this study to evaluate the accuracy of cath lab activation in a STEMI network with prehospital evaluation of ECG. Method: We performed an analysis of the STEMI network in Östergötland County, Sweden, including two spoke hospitals and one hub hospital. Patients presenting with definitive or suspected MI either with direct admission to the cath lab or admitted to a CCU between December 1, 2009 and November 30, 2011 were included. Patients were identified in the Swedish National Quality Registry (SWEDEHEART), and we then reviewed medical records including ECG, cardiac enzyme levels and clinical assessment to decide if patients had a STEMI. Results: Of 675 patients admitted directly to the cath lab, 554 were judged as STEMI resulting in a general accuracy of 82%. We then measured the accuracy for the different ways of arrival at the cath lab, resulting in 89% (355/399) for patients admitted from the ambulance, 74% (140/190) for patients admitted from emergency wards, and 69% (59/86) for patients admitted from any other hospital ward. Of all 652 patients judged as STEMI, 584 (90%) were either directly admitted to the cath lab or referred from the ambulance directly to the CCU of the hub hospital for clinical evaluation. The remaining group of 68 patients contained 22 patients presenting with symptom onset more than 12 hours before their first medical contact, and 26 patients with comorbidity as contraindication for primary PCI. Conclusion: In our STEMI network we found a high rate of accuracy for cath lab activation at 82%, without reducing direct admittance of STEMI patients. High accuracy for cath lab activation with maintained high rate of direct admittance saves time, money and myocardium.
Un servicio médico de guardia como base para la vigilancia centinela de la gripe
Authors: J Turner, H Kelly
Journal: Eurosurveillance (2005)

La vigilancia de la gripe en los paises de la Union Europea comprende una red centinela de medicos generales que declaran los casos de sindromes gripales (Influenza-like illness, ILI), la recogida de muestras para las analisis virologicos y las declaraciones de diagnosticos de gripe enviadas por los laboratorios. En Victoria, Australia, se dispone de un sistema similar de vigilancia centinela, siendo definidas las ILI por ocurrencia de fiebre, tos y cansancio, y las temporadas gripales definidas por umbrales. Sin embargo, la coordinacion de los medicos generales centinela puede ser muy costosa, en tiempo y dinero. Durante las dos ultimas temporadas gripales, se utilizo un servicio de medicos de guardia como sistema centinela para la vigilancia de la gripe. No se conoce otro sistema igual en ninguna parte del mundo. Las comparaciones tanto retrospectivas como prospectivas mostraron que los patrones de vigilancia de ILI de los medicos generales centinela son similares a los del servicio de medicos de guardia. Gracias a su rapidez y flexibilidad, variedad de pacientes y su distribucion geografica, la vigilancia hecha por un servicio de medicos de guardia es capaz de reemplazar la vigilancia centinela, e incluso de desempenar un papel importante en el reconocimiento de los patrones de enfermedades emergentes. Esto muy probablemente sea cierto no solo en Australia sino tambien en los paises de la Union Europea.
P1.07-020 Autoantibody Profiles of Cancer-Testis Genes in Non-Small Cell Lung Cancer
Authors: D. Djureinovic, C. Hellström, T. Dodig-Crnkovic, F. Ponten, M. Bergqvist, G. Holgersson, J. Schwenk, P. Micke
Journal: Journal of Thoracic Oncology (2017)
RTHP-20. RADIATION THERAPY TARGETING ACCURACY WHEN COMBINED WITH ALTERNATING ELECTRIC FIELD THERAPY
Authors: Jimm Grimm, Joseph Moore, Ted Hooker, Rachel Grimm, Ellen Huang, Juan Jackson, Kristin Redmond, Lawrence Kleinberg
Journal: Neuro-Oncology (2017)

Tumor treating fields (TTFields) is a noninvasive, regional antimitotic treatment approved for the treatment of newly-diagnosed and recurrent glioblastoma (GBM) including use concurrent with temozolomide. As anti-mitotic therapies may have synergy with radiotherapy, we have developed a plan to implement use of this therapy during radiotherapy and to test safety and tolerability. In preparation for the clinical trial, we plan tests evaluating impact of placement of the applicator (transducer array) on RT targeting and dosimetry using an anthropomorphic phantom, aquaplast immobilization, and intensity-modulated radiotherapy. In this first test, several strategies were employed to ensure minimal degradation of targeting accuracy: 1) the CT scan artifacts due to the array were reduced by use of the Metal Artifact Reduction for Orthopedic Implants (O-MAR) algorithm, 2) radiation was delivered to a tumor location that did not require the radiation beam to pass through the array, by using an arrangement of six noncoplanar intensity modulated radiation therapy (IMRT) beams entering inferiorly, 3) the cone beam CT (CBCT) alignment was performed with a region of interest box that excluded any of the arrays. The end result was an X,Y,Z targeting error of 0.58 mm, -0.59 mm, 0.40 mm, for a 3D Euclidean error of 0.92 mm, well within the acceptable range for GBM irradiation. An extensive series of systematic tests of comprehensive geometries is planned to determine the accuracy in various tumor locations and geometries including dosimetric effects. The data obtained from these preclinical investigations, when completed, will support optimal testing of concurrent TTFields and radiation for safety/tolerability and ultimately efficacy.
STEM-11. A MAPK-DRIVEN miR-124-SOX9 AXIS IS CRITICAL FOR STEM CELL MAINTENANCE, PROGRESSION, AND THERAPY-RESISTANCE IN GLIOBLASTOMA
Authors: Hanna Sabelstrom, Rebecca Petri, Ksenya Shchors, Rahul Jandial, Rohit Sacheva, Selma Masic, Edith Yuan, Trenten Fenster, Theo Nicolaides, Shirin IIkhanizadeh, Mitchel S Berger, Evan Snyder, William Weiss, Johan Jakobsson, Anders Persson
Journal: Neuro-Oncology (2017)

Glioblastoma (GBM) is the most common and aggressive malignant primary brain tumor. Genetic alterations in growth factor signaling pathways are found in 90% of GBMs. Advances in developmental and glioma biology suggest that common down-stream effector molecules in growth factor signaling pathways are critical for stem cell maintenance in the normal brain and GBM cells. It remains unclear whether differentiation therapies will be of therapeutic value for GBM patients. Here, we demonstrate that constitutive mitogen activated protein kinase (MAPK) activation in stem cells drives GBM formation and blocks neurogenesis in mice. Pharmacological inhibition of MAPK signaling restored neurogenesis in vivo and induced neuronal differentiation in GBM tumorspheres cultures established from murine GBMs and patient-derived tumors. Inhibition of MAPK signaling depleted SOX9 protein expression, and to a lesser extent SOX9 mRNA levels, in GBM cells. MicroRNA profiling experiments demonstrated that MAPK signaling regulates genome-wide expression of miRNAs, including the neuronal determinant miR-124. Pharmacological inhibition of MAPK signaling increased miR-124 levels in SOX9-expressing GBMs, but not SOX10-expressing proneural tumors. Using a doxycycline-inducible approach in vitro and in vivo, we demonstrated that miR-124 overexpression blocks SOX9 expression and induces neuronal differentiation in an EGFRvIII-driven GBM model and patient-derived xenografts. Neuronal differentiation resulted in apoptosis, reduced DNA repair capacity, and radiosensitized GBM cells. Doxycycline-mediated miR-124 overexpression resulted in complete regression for 1/3 of patient-derived xenografts. Mechanistic studies showed that SOX9 was a direct target of miR-124 and a major regulator of stem cell maintenance in GBM. Preliminary data showed that MAPK activation regulates transcriptional networks in SOX10-expressing proneural glioma, suggesting that distinct miRNAs regulate glioma aggressiveness in a subtype-specific manner. In conclusion, our results provide a mechanistic explanation for MAPK-dependent expansion of the stem cell pool during GBM initiation and demonstrate that enforcing neuronal differentiation represents a viable therapeutic strategy in glioma.
Surto de sarampo na região Provence-Alpes-Côte d’Azur, França, Janeiro-Julho 2003
Authors: C Six, F Franke, K Mantey, C Zandotti, F Freymuth, F Wild, I Parent du Châtelet, P Malfait
Journal: Eurosurveillance (2005)

No fim de maio de 2003, o laboratorio de virologia do Centro hospitario de Marseille informou o Instituto de Saude Publica frances que existiam cinco casos confirmados de sarampo em jovens adultos que viviam em Marseille. Foi realisado um inquerito pela Unidade interregional de epidemiologia Sul em varios servicios sanitarios communitarios e hospitalares para determinar a circulacao do virus na regiao Provence-Alpes-Cote d’Azur (PACA). A investigacao permitiu de identificar 259 casos : 183 casos clinicos, 74 casos confirmados serologicamente e dois casos ligados epidemiologicamente. Os primeiros casos foram identificados durante os seis primeiros meses de 2003, com um pico em Abril. Este surto de sarampo na regiao PACA foi favorecido pela baixa cobertura vacinal que criou grupos de populacao susceptiveis. O numero de casos foi provavelmente superior ao identificado. Este relatorio mostra os limites do sistema de vigilância do sarampo em Franca: a rede sentinela nao tinha detectado nenhum caso nesse periodo. A Franca deve alcancar o objetivo da OMS de erradicacao do sarampo em 2010 e as ferramentas de vigilância devem ser as que ja se usam na maioria dos paises mais adiantados no processo de erradicacao. Para alcancar este objetivo, a Direccao Geral da Saude designou um grupo de trabalho em carga de propor um plano nacional para interromper a transmissao autoctone do sarampo em Franca.
Clinical Significance of Plasma Epstein-Barr Virus DNA in Pulmonary Lymphoepithelioma-like Carcinoma (LELC) Patients
Authors: Mian Xie, Xiaojun Wu, Fang Wang, Jinjun Zhang, Xiaosong Ben, Jiexia Zhang, Xiaoxiang Li
Journal: Journal of Thoracic Oncology (2017)
P3.02-008 Non-Invasive Diagnosis of Solitary Pulmonary Nodules Using High-Throughput Targeted DNA Methylation Sequencing of Circulating Tumor DNA
Authors: W. Liang, Y. Zhao, W. Huang, Y. Gao, W. Wang, W. Xu, L. Li, H. Shen, X. Fu, P. Laird, J. Fan, X. Cai, J. He
Journal: Journal of Thoracic Oncology (2017)
Note on the Enzymatic Activity of a Transplanted Adenocarcinoma of the Glandular Stomach of a Mouse
Authors: Jesse P. Greenstein, Harold L. Stewart
Journal: JNCI Journal of the National Cancer Institute (1942)

Note on the Enzymatic Activity of a Transplanted Adenocarcinoma of the Glandular Stomach of a Mouse Jesse P. Greenstein, Jesse P. Greenstein senior biochemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Harold L. Stewart Harold L. Stewart senior pathologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 2, Issue 6, June 1942, Pages 631–633, https://doi.org/10.1093/jnci/2.6.631 Published: 01 June 1942
Desarrollo de una red para la investigación de los agentes patógenos emergentes transmitidos por alimentos en Alemania
Authors: D Werber, A Ammon
Journal: Eurosurveillance (2000)

Se ha creado en Alemania una red de epidemiologos, microbiologos, veterinarios y clinicos con el fin de dar apoyo a los departamentos sanitarios y a las autoridades veterinarias locales en la investigacion y estudios epidemiologicos de los agentes patogenos emergentes transmitidos por alimentos. Este articulo describe los metodos que se utilizan para el estudio de Escherichia coli enterohemorragica (ECEH) y el sindrome hemolitico uremico (SHU).
Une épidémie décroissante de LGV aux Pays-Bas en 2004 et 2005
Authors: M J W van de Laar, F. D.H. Koedijk, H Götz, H Jc de Vries
Journal: Eurosurveillance (2006)

En 2004, une epidemie de LGV a ete detectee chez des hommes ayant des relations sexuelles avec d’autres hommes aux Pays-Bas. En janvier 2006, 179 cas confirmes de LGV avaient ete declares : 65 retrospectivement en 2002/2003, 76 en 2004 et 38 en 2005. 
L’evolution de l’epidemie de LGV semble avoir ralenti et seuls quelques cas ont ete identifies au cours des premiers mois de 2006.
OA 04.02 Feasibility of Pulmonary Resection Following Definitive Chemoradiotherapy for Primary Lung Carcinoma
Authors: Y. Hida, K. Kaga, T. Kato, M. Aragaki, R. Nakada-Kubota, Y. Yagi, R. Chiba, Y. Matsui
Journal: Journal of Thoracic Oncology (2017)